Business

Sudarshan Pharma Industries in Spotlight After 325% Stock Surge Over Five Years

Despite a slight dip of 1.99% on Friday, closing at ?26.66 per share on May 2, the stock remains a multibagger, having multiplied investors’ wealth significantly over the past half-decade. The company now boasts a market capitalization of ?642 crore.

• By Newsdesk
• New Delhi
• May 05, 2025

Business

Sudarshan Pharma Industries Ltd. (SPIL), a mid-sized pharmaceutical company, is drawing attention from investors this week following the release of its latest financial results — and a remarkable stock performance that has seen its share price soar over 325% in just five years.

Despite a slight dip of 1.99% on Friday, closing at ₹26.66 per share on May 2, the stock remains a multibagger, having multiplied investors’ wealth significantly over the past half-decade. The company now boasts a market capitalization of ₹642 crore.

Strong Financial Performance in H2 FY25

SPIL reported a 19% increase in net sales, reaching ₹277 crore for the second half of FY25, while net profit jumped by an impressive 43% to ₹7 crore compared to the same period last year. On an annual basis, the company’s performance was equally robust — full-year net sales rose 9% to ₹505 crore, with net profit climbing 45% to ₹16 crore.

These gains were underpinned by a strategic focus on expanding exports, boosting domestic sales of manufactured medicines, and improving margins from its API (Active Pharmaceutical Ingredient) resale segment. The company highlighted in its investor presentation that these efforts led to a sharp improvement in EBITDA margins, contributing to the growth in net profits.

Over the past five years, SPIL has delivered a compound annual growth rate (CAGR) of 37% in profit — a figure that underscores the company's consistent performance and operational efficiency.

Riding the Wave of India’s Expanding Pharma Sector

Sudarshan Pharma’s upward trajectory aligns with the broader growth story of India’s pharmaceutical sector. Valued at $42 billion in 2021, the industry is expected to grow to around $66 billion by 2025, with projections suggesting it could reach up to $130 billion by 2030. India is a critical player globally, supplying 40% of the U.S.’s generic drug needs and 60% of the world’s vaccines.

Founded in 2008, SPIL operates across the pharmaceutical value chain — from chemical intermediates and APIs to finished formulations — offering a fully integrated manufacturing and sourcing capability.

As Sudarshan Pharma builds on its strategic initiatives and continues to capitalize on sector-wide tailwinds, investors are likely to keep a close watch on this high-performing stock in the sessions ahead.